On March 10, 2021, in shandong province and drug administration for my company issued by the pharmaceutical production license, marked the way or pharmacy in such aspects as drug quality management and production completely meet the pharmaceutical production conditions, the company developed by chemical intermediates for manufacturing enterprise to API production enterprise transformation and upgrading of the important milestone.

A total of 6 API varieties were applied for this "Drug Production License", including 5 generic APIs: cecoxib, fumarate and voonasan, fapilavir, calcium gluconate and dopamine hydrochloride; 1 national second class new drug: L-pyroglutamate monolasan.

At the beginning of its establishment, Harway Pharma Co., Ltd. took "innovation and entrepreneurship for the cause human health" as the mission of the company. The drug production license was approved, which means that Dahe Pharmaceutical officially entered the field of pharmaceutical production and truly became a pharmaceutical manufacturing enterprise to further realize the mission of the company. We are willing to practice the "spirit of contract" together with like-minded partners, and work together to "make the common people have access to and can afford the safe medicine we developed". We will live up to our time and forge ahead!